Search Results

Total 48 documents found.

•  

• Building Toward Leadership in Oncology Deborah Dunsire, MD President and Chief Executive Officer, Millennium: The Takeda Oncology Company Disclaimer This presentation contains forward-looking statements regarding the Company's plans, outlook, strategies, and results for the future. All f d l ki t t t b d j d t d i d f th i f ti il bl t thAll forward-looking statements are based on judgments derived from the information available to the Company at this time. Forward-looking statements can sometimes be identified by the use of forwardlooking words such as "may," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "continue," "seek," "pro forma," "potential," "target," "forecast," "intend" or other similar words or expressions of the negative thereof. Certain risks and uncertainties could cause the Company's actual results to differ materially from any forward-looking statements contained in this presentation. These risks and uncertainties include, but are not limited to: (1) the

• Research Alliances
• While continuing to improve its own R&D capabilities, Takeda actively pursues alliances with other pharmaceutical manufacturers, biotechnology companies, universities, and other research institutions to efficiently introduce key technologies.

• Therapeutic and Technology Areas sought by Takeda
• We describe the therapeutic areas that Takeda places priority on, under the background of our wealth of knowledge and expertise, together with a challenging therapeutic area, into which Takeda plans to explore with joining the new market. It is also aggressively exploring unique drug-development technologies.

• X. Pipeline Development Activities ■ New compounds ■ Additional indications/new formulations ■ Recent progress in stage ■ Discontinued project ■ Characteristics of projects ■ Other alliance projects ■ Clinical study protocol summaries ■ Outcome studies Research Activities ■ Main joint research activities - 17 - Development activities New Compounds Development code Drug Class (administration route) Indications Stage In-house/ In-license MEPACT Immunostimulant (injection) Non-metastatic osteosarcoma EU Approved (Mar 09) In-house SYR-322 DPP-4 inhibitor (oral) Diabetes mellitus Diabetes mellitus (Fixed-dose combination with Actos) Diabetes mellitus (Concomitant therapy with thiazolidinediones) Diabetes mellitus (Fixed-dose combination with metformin) US Jpn EU US Jpn EU Jpn - FDA Complete Response Letter (Jun 09) Filed (Sep 08) P-III FDA Complete Response Letter (Sep 09) Filed (Jun 09) P-III Filed (Jun 09) P-I In-house TAK-375 MT1/MT2 receptor agoni

• Takeda Research & DevelopmentTakeda Research & Development Strategy: To 2020 and beyond -Challenge to R&D productivity improvement and innovationShigenori Ohkawa, Ph. D Chief Scientific Officer Takeda Pharmaceutical Company Limited Executive summery The mission of Takeda R&D is to achieve better health for individuals and progress in medicine, by using cutting-edge science to develop superior pharmaceutical products that fill unmet needs. To fulfill this mission, between 2006 and 2010, we enriched our pipeline, established a global organization and enhanced our R&D capability. The 2010-2012 mid-range plan builds on these achievement and will accelerate progress toward our goal. To further enrich our R&D pipeline and grow as a global pharmaceutical company, the plan: Maximizes the value of the portfolio, mainly by emphasizing late-stage clinical programs that support near-term growth Clarifies and promote TA strategy to fulfill unmet needs by leveraging Takeda's assets Concurrently, we aim to improve efficien

• 2010 2012 Mid R Pl2010-2012 Mid-Range Plan May 12, 2010 - Transformation for a New Takeda - Yasuchika Hasegawa President & CEO Takeda Pharmaceutical Company Limited Agenda 1 Outcome of 2006-2010 Mid-Range Plan 2 2010-2012 Mid-Range Plan 3 Forecasts for Financial Results 4 Strategic Investments and Returns to Shareholders 2 Operational targets in FY2010 and Results as of End of FY2009 Outcome of 2006-2010 Mid-Range Plan Achievements to date on 2006-2010 Mid-Range Plan Enhancement of R&D pipeline, toward sales of in-house ethical products of 2 trillion yen in FY2015 Not achieved Sales of in-house ethical products: 1.4 trillion yen Not achieved (1.2 trillion yen) Market share*: 2.5% 2.5% (Forecast) *Weighted average of countries where Takeda has its own sales channels R&D expenses: investment up to 20% of the sales of ethical products 22.1% EPS*: CAGR of more than 7% 7.8% (FY2006-FY2009) *Excluding extraordinary income/loss and other extraordinary factors ROE : Maintenance of 14 15% level 14 4% 3 Returns to Sha

• FFiinnaanncciiaall RReessuullttss ffoorr 11sstt HHaallff FFYY22000099 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2037 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/financial/index.html 2006-2010 Medium-Term Plan Growth toward a World-class Pharmaceutical Company 1. Enhancement of capability to create new drugs through in-house R&D activities ・ Thorough review of the R&D management scheme and investments focused on the global research infrastructure ・ Building a structure that will enable continued launch of new products from its in-house R&D from fiscal 2011 ・ Enhancement of the R&D pipeline to a level where the company can expect ethical drugs sales* (consolidated basis) of 2 trillion yen in fiscal 2015 *Excluding sales of products for which Takeda acts as a distributor to wholesalers 2. Formulation of a tri-polar marketing function (Japan, USA, Europe) ・ Solidifying market

• Consolidated ResultsConsolidated Results Third Quarter of Fiscal 2009 Hiroshi Takahara Corporate Officer General Manager Finance & Accounting Department FY08 Apr-Dec FY09 Apr-Dec billions of yen billions of yen billions of yen Year-on-year change Consolidated Results Summary Net Sales 1,202.8 1,127.9 - 74.8 - 6.2% Gross Profit 981.5 913.3 - 68.2 - 6.9% SG&A Expenses 364.0 347.8 - 16.2 - 4.4% Excluding Intangible Fixed Assets & Goodw ill Amortization Costs 302.0 284.7 - 17.3 - 5.7% R&D Expenses 377.6 209.3 - 168.3 - 44.6% Excluding IPR&D expenses 214.1 209.3 - 4.8 - 2.2% Operating Income 239 9 356 2 + 116 3 + 48 5%Operating Income 239.9 356.2 + 116.3 + 48.5% Excluding Extraordinary Factors 465.6 419.5 - 46.1 - 9.9% Net Income 168.6 259.1 + 90.6 + 53.7% Excluding Extraordinary Income/Loss & Other Extraordinary Factors 302.0 303.2 + 1.2 + 0.4% E P S * 370.71 yen 384.04 yen + 13.33 yen + 3.6% * Excluding Extraordinary Income/Loss & Other Extraordinary Factors 1 Year-on-year Increase Currency Translation Effect (

• Takeda has designated four core therapeutic areas within its operations: lifestyle-related diseases; oncology and urological diseases (including gynecological disorders); central nervous system diseases (including bone and joint disorders); and gastroenterological diseases. We are actively pursuing business in these fields based on our Tikarakobu Research Strategy, which is designed to enable focused deployment of research resources and the diversification of risk. The oncology field in particular is a key therapeutic area, second only to lifestyle-related diseases among our four core therapeutic areas. We formulated our R&D strategy for oncology around Millennium Pharmaceuticals, Inc., and we are pooling all the capabilities of our R&D centers worldwide to strengthen our pipeline for this field. Thanks to progress in genome analysis and related areas, pharmaceutical research has benefited from a dramatic increase in the number of novel drug discovery targets. However, the probability of success at the clini

• 4 M e s s a g e Yasuchika Hasegawa President & CEO Message to Stakeholders 5 Takeda's challenge is to realize its goal of becoming a "world-class pharmaceutical company." In the fiscal year ended March 31, 2009 (fiscal 2008), Takeda made significant progress toward realizing this goal through its largest ever strategic investment. In the pursuing year, the Company successfully integrated the world-class biopharmaceutical firm Millennium Pharmaceuticals, Inc. (Millennium) into the Takeda Group, based on a medium-to-long-term growth strategy of developing our core next-generation business in oncology. In addition to this, Takeda successfully realigned its operating structure in the world's largest pharmaceutical market, the U.S., through the division of TAP Pharmaceutical Products Inc. (TAP)a 30-year joint venture with Abbott Laboratories. Following the consolidation of TAP as a wholly-owned subsidiary, the sales and marketing functions of TAP were merged into our U.S. subsidiary Takeda Pharmaceuticals North A

• 17 X. Pipeline Development Activities ■ New compounds ■ Additional indications/new formulations ■ Characteristics of projects ■ Other alliance projects ■ Clinical study protocol summaries ■ Outcome studies Research Activities ■ Main joint research activities 18 Development activities ■ New Compounds Development code Drug Class (administration route) Indications Stage In-house/ In-license SYR-322 DPP-4 inhibitor (oral) Diabetes mellitus Diabetes mellitus (Fixed-dose combination with ACTOS) US Jpn EU US EU Filed (Dec 07) Filed (Sep 08) P-III Filed (Sep 08) P-III In-house TAK-390MR Proton pump inhibitor (oral) Erosive esophagitis (healing and maintenance) and non-erosive gastro-esophageal reflux disease US Jpn Filed (Dec 07) P-II In-house TAK-375 MT1/MT2 receptor agonist (oral) Insomnia Circadian rhythm sleep disorder (CRSD) EU Jpn US P-III *Re-submission of a MAA is under consideration Filed (Feb 08) P-II In-house Vectibix TM Fully

• FFiinnaanncciiaall RReessuullttss ffoorr 11sstt HHaallff FFYY22000088 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2037 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/financial/index.html 2006-2010 Medium-Term Plan Growth toward a World-class Pharmaceutical Company 1. Enhancement of capability to create new drugs through in-house R&D activities ・ Thorough review of the R&D management scheme and investments focused on the global research infrastructure ・ Building a structure that will enable continued launch of new products from its in-house R&D from fiscal 2011 ・ Enhancement of the R&D pipeline to a level where the company can expect ethical drugs sales* (consolidated basis) of 2 trillion yen in fiscal 2015 *Excluding sales of products for which Takeda acts as a distributor to wholesalers 2. Formulation of a tri-polar marketing function (Japan, USA, Europe) ・ Solidifying market

• FFiinnaanncciiaall RReessuullttss ffoorr FFYY22000088 DATA BOOK Takeda Pharmaceutical Company Limited (TSE code 4502) Contact: Corporate Communications Dept. TEL: +81-3-3278-2037 FAX: +81-3-3278-2741 http://www.takeda.com/ Financial News http://www.takeda.com/financial/index.html 2006-2010 Medium-Term Plan Growth toward a World-class Pharmaceutical Company 1. Enhancement of capability to create new drugs through in-house R&D activities ・ Thorough review of the R&D management scheme and investments focused on the global research infrastructure ・ Building a structure that will enable continued launch of new products from its in-house R&D from fiscal 2011 ・ Enhancement of the R&D pipeline to a level where the company can expect ethical drugs sales* (consolidated basis) of 2 trillion yen in fiscal 2015 *Excluding sales of products for which Takeda acts as a distributor to wholesalers 2. Formulation of a tri-polar marketing function (Japan, USA, Europe) ・ Solidifying market function in each

• 17 X. Pipeline Development Activities ■ New compounds ■ Additional indications/new formulations ■ Characteristics of projects ■ Other alliance projects ■ Clinical study protocol summaries ■ Outcome studies Research Activities ■ Main joint research activities 18 Development activities New Compounds Development code Drug Class (administration route) Indications Stage In-house/ In-license SYR-322 DPP-4 inhibitor (oral) Diabetes mellitus Diabetes mellitus (Fixed-dose combination with Actos) US Jpn EU US EU Jpn Filed (Dec 07) Filed (Sep 08) P-III Filed (Sep 08) P-III P-I In-house TAK-390MR Proton pump inhibitor (oral) Erosive esophagitis (healing and maintenance) and non-erosive gastro-esophageal reflux disease US Jpn Approved (Jan 09) P-II In-house TMX-67 Non-purine, selective xanthine oxidase inhibitor (oral) Hyperuricemia in patients with gout US Approved (Feb 09) In-license (Teijin) TAK-375 MT1/MT2 receptor agonist (oral) Insomnia J

• ANNUALREPORT2008 Annual Report 2008 Our Contribution to Financial and Social Responsibility TakedaPharmaceuticalCompanyLimited Contributes to The Health of Individuals Worldwide 1 This annual report includes forward-looking statements regarding Takeda's plans, prospects, strategies and accomplishments, etc. These prospects are the result of assessment obtained from information currently available, and since the actual performance could be influenced by various risks and uncertainties, it shall be noted that the course of action could differ substantially from those prospects. Factors that could affect future prospects would include, but are not limited to, economic circumstances surrounding Takeda's domain identity, competitive pressures, relevant laws and regulations, change in the status of product development, exchange rate risk and so on. Precautions Regarding Forward-Looking Statements Takeda has issued an integrated Annual and CSR Report since fiscal 2006, in order to facilitate a comprehensive underst

• 32 Pipeline represents ethical drugs under development, from the start of research to approval/launching. Clinical trials are conducted on humans for drugs for which basic research and nonclinical trials have already been completed. Through the procedures of three-phased clinical trials and following efficacy and safety evaluation, the pipelines are launched onto the market as new drugs after approval by the regulatory authorities. Implemented for a small group of healthy adults in order to evaluate safety and ADME (Absorption, Distribution, Metabolism, Excretion) of the drug. R&D Pipeline SYR-322 is a promising pipeline for the treatment of diabetes, following our core product: Actos. SYR-322 was founded by Takeda San Diego, Inc. (TSD) as a therapeutic agent for Type 2 diabetes, with a DPP-4* inhibitory action. In December 2007, SYR-322 was submitted for a New Drug Application in the U.S. Major Promising Pipelines as Next-Generation Core Products ■Anti-Diabetic Drug: SYR-322 TAK-491 is positioned as a succ

• SUMMARY OF FINANCIAL STATEMENTS (Consolidated) First quarter results for the fiscal year ending March 31, 2008 These financial statements have been prepared for reference only, in accordance with accounting principles and practices generally accepted in Japan. July 31, 2007 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code : 4502 URL : http://www.takeda.co.jp/ Representative: Yasuchika Hasegawa, President Contact : Hirofumi Inoue, General Manager, Corporate Communications Department Tel : +81 3 3278-2037 1. First Quarter Consolidated Financial Results (April 1, 2007 to June 30, 2007) for the Fiscal Year Ending March 31, 2008 (1) Consolidated Operating Results Millions of yen, rounded to the nearest million (Percentages shown in columns below represent changes from the quarterly results for the same quarter in the previous year and the full-year results for the previous year, respectively.) Three months ended June 30, 2007 Three months ended June 30, 2006

• ANNUALREPORT2007 Annual Report 2007 Our Contribution to Financial and Social Responsibility TakedaPharmaceuticalCompanyLimited Contributes to The Health of Individuals Worldwide The image in the globe: the molecular representation of ramelteon (Rozerem ), insomnia medication This annual report includes forward-looking statements regarding Takeda's plans, prospects, strategies and accomplishments, etc. These prospects are the result of assessment obtained from information currently available, and since the actual performance could be influenced by various risks and uncertainty, it shall be noted that the course of action could differ substantially from those prospects. Factors that could affect future prospects would include, but are not limited to, economic circumstances surrounding Takeda's domain identity, competitive pressures, relevant laws and regulations, change in the status of product development, exchange rate risk and so on. Precautions Regarding Forward-Looking Statements Aiming to facilitate unde

• Takeda positions lifestyle-related diseases, oncology and urological diseases (including gynecological disorders), central nervous system diseases (including bone and joint diseases) and gastroenterological diseases as the four core therapeutic areas and has been promoting efforts based on the Tikarakobu Research Strategy, by reestablishing research strategies geared toward achieving our goal of the 2006-2010 Medium-Term Management Plan. The Tikarakobu Research Strategy aims to balance the "research resources concentration" and the "diversification of risk" by focusing and enriching the research themes in the strategy via the setting of drug categories which should be prioritized, and with the external environment, such as market and research trends, as well as the our strength, including the previous R&D achievements of the company, in mind. Through this initiative, we devote all our resources to achieving the final goal of launching new products onto the market, while effectively utilizing research resourc

• 1 1 Takeda Pharmaceutical Company Limited President Yasuchika Hasegawa November 7, 2006 Management PolicyManagement Policy First half in Fiscal 2006 2 Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited 2006-2010 Medium-Term Management Plan Approaches toward lean andApproaches toward lean and solid structuresolid structure 9595--0000 PlanPlan 0101--0505 PlanPlan 〜〜 Growth Toward aGrowth Toward a ""WorldWorld--Class PharmaceuticalClass Pharmaceutical Company with Japanese Origin, as based on TakedaCompany with Japanese Origin, as based on Takeda--ismism""〜〜20062006--20102010 MediumMedium--TermTerm Management PlanManagement Plan New growth stage toward aNew growth stage toward a ""WorldWorld--class pharmaceuticalclass pharmaceutical companycompany"" 2 3 Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited 2006 2010 Medium-Term Management Plan Financial Goals Sales: mid-single digit growth R&D: high-single digit increase Net income: low-single digit growth EPS: m

Pages:[1] [2] [3]   Next